Circulating Macrophage Activation Markers Predict Transplant-Free Survival in Patients With Primary Sclerosing Cholangitis

Show simple item record Bossen, Lars Vesterhus, Mette Hov, Johannes R. Färkkilä, Martti Rosenberg, William M. Moller, Holger J. Boberg, Kirsten M. Karlsen, Tom H. Gronbaek, Henning 2021-09-16T12:28:02Z 2021-09-16T12:28:02Z 2021-03
dc.identifier.citation Bossen , L , Vesterhus , M , Hov , J R , Färkkilä , M , Rosenberg , W M , Moller , H J , Boberg , K M , Karlsen , T H & Gronbaek , H 2021 , ' Circulating Macrophage Activation Markers Predict Transplant-Free Survival in Patients With Primary Sclerosing Cholangitis ' , Clinical and translational gastroenterology , vol. 12 , no. 3 , 00315 .
dc.identifier.other PURE: 168513318
dc.identifier.other PURE UUID: c2a5e328-82ae-4ae7-b0b9-c7e7e5062f94
dc.identifier.other WOS: 000681351500002
dc.identifier.other ORCID: /0000-0002-0250-8559/work/100083075
dc.description.abstract INTRODUCTION: Primary sclerosing cholangitis (PSC) is a progressive liver disease characterized by bile duct inflammation and fibrosis. The role of macrophages in PSC development and progression is less studied. Macrophage activation markers soluble (s)CD163 and mannose receptor (sMR) are associated with disease severity and outcome in other liver diseases, but not previously investigated in PSC. We evaluated sCD163 and sMR regarding disease severity and prognosis in patients with PSC. METHODS: We investigated 2 independent PSC cohorts from Oslo (n = 138) and Helsinki (n = 159) and analyzed blood sCD163 and sMR levels. The Mayo score, Enhanced Liver Fibrosis Test, and Amsterdam-Oxford model were assessed for comparison. RESULTS: Median (interquartile range) sCD163 was 3.32 (2.27-5.60) and 1.96 (1.47-2.70) mg/L in the Oslo and Helsinki cohorts, respectively, reflecting differences in disease severity between cohorts. Median sMR was similar in both cohorts, 0.28 (0.22-0.44) and 0.28 mg/L (0.20-0.36), respectively. In both cohorts, sCD163 and sMR levels raised with increasing disease severity (liver enzymes, Mayo score, and enhanced liver fibrosis test). Patients with high baseline levels of sCD163 had shorter transplant-free survival than patients with low baseline levels. Furthermore, sCD163 was associated with transplant-free survival in univariate cox-regression analyses. Both sCD163 and sMR performed better in the Oslo cohort of more severely diseased patients than those in the Helsinki cohort of more mildly diseased patients. DISCUSSION: Macrophage activation markers are elevated according to disease severity suggesting an important role of macrophages in PSC. Furthermore, sCD163 was identified as a prognostic marker and predictor of transplant-free survival in PSC (see Visual Abstract, Supplementary Digital Content 4, [GRAPHICS] en
dc.format.extent 9
dc.language.iso eng
dc.relation.ispartof Clinical and translational gastroenterology
dc.rights cc_by_nc_nd
dc.rights.uri info:eu-repo/semantics/openAccess
dc.subject SOLUBLE CD163
dc.subject HEPATITIS-B
dc.subject LIVER
dc.subject FIBROSIS
dc.subject MANAGEMENT
dc.subject DISEASE
dc.subject SCD163
dc.subject 3121 General medicine, internal medicine and other clinical medicine
dc.title Circulating Macrophage Activation Markers Predict Transplant-Free Survival in Patients With Primary Sclerosing Cholangitis en
dc.type Article
dc.contributor.organization Centre of Excellence in Complex Disease Genetics
dc.contributor.organization HUS Abdominal Center
dc.contributor.organization Department of Medicine
dc.contributor.organization Clinicum
dc.contributor.organization Gastroenterologian yksikkö
dc.description.reviewstatus Peer reviewed
dc.relation.issn 2155-384X
dc.rights.accesslevel openAccess
dc.type.version publishedVersion

Files in this item

Total number of downloads: Loading...

Files Size Format View
Circulating_Mac ... tion_Markers_Predict.4.pdf 634.6Kb PDF View/Open

This item appears in the following Collection(s)

Show simple item record